Miju LabsRx-LLM is the one good public pharmacy benchmark, and its scores say the work is not done. Six tasks, 250 input-output pairs each, 1,500 pairs total, public on GitHub. Drug-indication matching is essentially solved at 97.6% and sig generation at 88.0%. But drug–drug interaction identification sits at 70.4% and drug formulation matching at F1 54.0% — and there is no deprescribing task at all (PMC, GitHub).
Drug interactions at 70% is a clinically consequential failure rate on a task pharmacists perform hundreds of times a day. Deprescribing against Beers and STOPP/START — the judgement that removes a drug from a frail patient's list — has no benchmark anywhere.
So the artefact is well-defined, the headroom is measured, the pool is verifiable at near-zero cost, and no patient data is required. And then two facts break it.
Confirmed academic builders, two Mercor listings, and nothing else. A search across prior-authorisation and formulary AI vendors — Develop Health, Taction, the general "AI prior auth" category — found a lively vendor market and no evidence that any of them purchases pharmacist-labelled training or evaluation data. This is absence of evidence at the depth reached, not proof of absence [WEAK]. But it is the single fact that decides this niche.
What the artefact is
Six things, all definable on a synthetic patient with a drug list, an eGFR and a problem list:
- Drug-interaction severity and clinical-action labels — not just "interaction exists" but what the pharmacist does about it.
- Renal and hepatic dose-adjustment gold answers.
- Deprescribing recommendations against Beers criteria and STOPP/START. Unbenchmarked, and the highest-judgement task on the list.
- Sig generation and normalisation — prescription-order text in and out.
- Formulary and prior-authorisation determinations with the policy citation that carries the decision.
- Medication-reconciliation error detection across care transitions.
The common structure: each is a decision with a defensible rule behind it and a clinically meaningful action attached, which makes them cheap to specify and easy to adjudicate. Scope discipline applies as it does in Nursing — pharmacists may not diagnose, so artefacts stay in medication-therapy management. That is where the value is anyway.
Does it need patient data
No. Every task above is fully specified by a fictional patient carrying a drug list, a renal function value and a problem list. Rx-LLM is itself the existence proof: a published, public, GitHub-hosted benchmark built exactly this way.
There is no de-identification step, no human subject and no institutional data-ownership claim, for the same reasons set out in Build it without ever touching a patient record. Employer IP is a low risk here relative to every other niche — a pharmacist's judgement is portable and not chart-bound, so there is no equivalent of the coder who must not bring charts or the scribe who must not bring notes.
The sharp constraint is not privacy. It is reference-data licensing. The authoritative interaction and dosing content — Lexicomp, Micromedex, First Databank, Clinical Pharmacology, and the Beers Criteria via AGS — is proprietary and licensed. A pharmacist writing gold answers from professional knowledge is defensible. A pharmacist transcribing Lexicomp is a licensing breach, and the difference is invisible in the output. This must be designed into the annotation protocol explicitly, with a per-item attestation and a source-of-knowledge field, or the corpus is encumbered in a way a Series A diligence process will find.
That constraint is the same shape as Oncology's NCCN problem and Nursing's Schmitt-Thompson problem: the authoritative content in a clinical domain is usually somebody's copyright, and the product has to be built from judgement rather than from transcription.
Is anyone buying
Budget scores 2, and the 2 is generous.
Confirmed academic builders. Rx-LLM was built by the University of Colorado School of Medicine (Biomedical Informatics), CU Anschutz, Mayo Clinic, Cleveland Clinic and the University of Georgia College of Pharmacy, using a panel of 5 licensed board-certified critical-care pharmacists to review best practices and 2 board-certified pharmacists to review the datasets (PMC). That is a real expert panel with a real institutional sponsor — and academic sponsors do not renew.
Frontier labs, indirectly. Mercor lists Pharmacist at $75–120/hr and Pharmacy Prior Authorization & Specialty-Medication Access Specialist at $75/hr (Mercor). Two live bands is genuine demand — Mercor does not list roles it is not filling — but it is a rate card, not a contract, and no first-party lab posting anywhere names a PharmD, exactly as none names an RN or a CPC.
Commercial buyers: none found. The prior-authorisation and formulary AI vendor market is real and active (Develop Health, rxalmanac vendor list), and not one of them has been shown buying pharmacist-labelled data.
That gives pharmacy a budget score of 2 rather than Genomics and variant curation's 1 purely because two priced Mercor listings exist where genomics has none. It is not a distinction to build a business on.
Proof scores 4 despite this. If a buyer appears, being visibly the best source is fast: Rx-LLM's weak tasks are named and public, deprescribing is unclaimed, and BPS board certification gives a hard quality signal that no competitor is currently using.
What the expert costs
Cost scores 3, and the reason is arithmetic rather than infrastructure.
BLS, Pharmacists, May 2025: median $140,910/yr = $67.75/hr; 325,200 jobs; +5% 2025–2035, roughly 12,500 annual openings (BLS).
Against Mercor's $75–120/hr, the multiple is 1.1x to 1.8x. Compare Medical coding at roughly 3x and Behavioural and mental health at 2x to 5x. Pharmacists are not cheap relative to their alternative employment, and a niche where the expert's outside option is 90% of your sell price has almost no room for a vendor margin between them.
Put it plainly: at $75/hr sell and $67.75/hr opportunity cost, there is no business. The band only works at the $120/hr ceiling, which means the product has to be the high-judgement end — deprescribing, formulary adjudication, interaction severity with clinical action — and never the volume end. See What a clinician hour costs for the general form of this constraint, and Radiology for the case where the same arithmetic goes fully negative.
The pilot itself is cheap: no PHI, no equipment, no institutional agreement, twenty board-certified pharmacists and a case generator.
Getting to them
Reach scores 5. This is the best-organised pool in the dossier after coding.
Verification is easy and cheap. NABP's membership comprises the 50 state boards of pharmacy plus DC, Guam, Puerto Rico, the Virgin Islands and 10 Canadian provinces (NABP); NABP Verify provides pharmacist-credential verification (NABP); every state board runs its own public lookup; and NABP e-Profile IDs give each pharmacist a stable national identifier — a structural advantage that Behavioural and mental health conspicuously lacks.
Board certification is the quality filter, and it is verifiable. BPS credentials — BCPS, BCACP, BCCCP, BCOP and the rest — are a much stronger signal than a licence alone, and no competitor is using them because no competitor is here.
Channels: APhA, ASHP and ACCP, the state pharmacy associations, r/pharmacy, the Pharmacy Times and Drug Topics readership, and the BPS specialty communities. Professional-body attitude is neutral to positive — ASHP and APhA engage with AI as a practice tool, with no organised opposition found, in contrast to Nursing.
Where the benchmarks sit
| Task | Best score | Model |
|---|---|---|
| Drug-indication matching | 97.6% accuracy | LLaMA3-70B |
| Drug order (sig) generation | 88.0% accuracy | LLaMA3-70B |
| Renal dose identification | F1 83.3% | GPT-4o-mini |
| Drug route matching | F1 74.3% | LLaMA3-70B |
| Drug–drug interaction identification | 70.4% accuracy | GPT-4o-mini |
| Drug formulation matching | F1 54.0% | LLaMA3-70B |
| Deprescribing | No task exists | — |
Rx-LLM, six tasks, 1,500 pairs (PMC).
MedHELM's 121-task taxonomy contains exactly one medication dataset — MedicationQA, which is public and consumer-facing rather than clinical (arXiv 2505.23802). As with coding, an entire clinical domain is represented by a single dataset in the field's structural map.
Room scores 5 on the strength of that table. Deprescribing, formulary and prior-authorisation determinations, medication reconciliation and formulation matching are all unbenchmarked or badly benchmarked, and nobody is building. It is the joint-highest room score in the dossier alongside Genomics and variant curation — and for the same uncomfortable reason: the space is open because nobody is paying to close it. See The measurement landscape.
What would kill it
Defense scores 3.
The margin kills it first. A 1.1–1.8x multiple over market wage is not a spread; it is a rounding error with a vendor attached. Any pricing pressure at all — a buyer negotiating, a competitor undercutting, a pharmacist discovering the sell price — erases it. This is the constraint that should govern the decision, ahead of everything else on the page.
Absent buyers kill it second. A niche with no named commercial buyer is not a niche with a slow sales cycle; it is a hypothesis. The distinction matters because the remedy is different: you do not fix it with better positioning, you fix it by finding out.
What holds the position, if it exists at all: BPS board certification is a genuine credential barrier, reference-data licensing constraints mean the corpus has to be built from judgement rather than scraped, and drug knowledge refreshes continuously — new agents, new interactions, new formulary policy every quarter. That is a real subscription structure. It is just attached to a customer nobody has found.
The honest instruction is not "avoid" but "validate cheaply." Thirty minutes of direct outreach to Arine, Waltz Health and DrFirst — medication-management and pharmacy-benefit companies whose products plainly need pharmacist-grade ground truth — would settle whether a commercial buyer exists. If any one of them says yes, budget moves from 2 to 4 and this page's stance changes with it. If all three say no, the niche is closed and the finding is worth having. Nothing else in this dossier is that cheap to resolve, and no other page's verdict turns on so few phone calls.
Where the record is thin
There is no published national count of licensed pharmacists. NABP publishes none, so the BLS employment figure of 325,200 stands in for a licensed pool that is certainly larger — Veterinary medicine shows the licensed-versus-employed gap can run 45%.
Whether the two Mercor pharmacy listings are being filled, and for whom, is unknown. A published band proves a role is open; it does not prove a project exists behind it, or that the project recurs.
And there is no pricing information of any kind — no rate per gold answer, no cost per benchmark task, no disclosed engagement value. The Rx-LLM panel of seven pharmacists came with no compensation disclosure. Compare the ranked read in The health read.